Sirolimus for calcineurin inhibitors in organ transplantation: Contra

Kidney International

Volumn 78, Issue 11, 2010, Pages 1068-1074

  Cravedi, Paolo ^a   Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

proteinuria; renal transplantation; sirolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACNE; BONE MARROW SUPPRESSION; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; HYPERTRIGLYCERIDEMIA; INFERTILITY; INNATE IMMUNITY; INTERSTITIAL PNEUMONIA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG DISEASE; MOUTH ULCER; NEPHROTOXICITY; OVARY CYST; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

EID: 78349306789     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.268     Document Type: Short Survey

References (69)

1. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
2. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35: 7S-14S.
3. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
4. Morath C, Arns W, Schwenger V et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007; 22(Suppl 8): viii61-viii65.
5. Russ G, Segoloni G, Oberbauer R et al. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80: 1204-1211.
6. Tomlanovich SJ, Vincenti F. Sirolimus: defining nephrotoxicity in the renal transplant recipient. Clin J Am Soc Nephrol 2007; 2: 198-199.
7. Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460: 108-112.
8. Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111-1131.
9. Chang SH, Russ GR, Chadban SJ et al. Trends in adult post-kidney transplant immunosuppressive use in Australia, 1991-2005. Nephrology (Carlton) 2008; 13: 171-176.
10. 2008 OPTN/SRTR Annual Report, available at http://www.ustransplant.org. Accessed on 27 July, 2010.
11. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
12. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
13. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
14. Jones DL, Sacks SH, Wong W. Controlling the generation and function of human CD8+ memory T cells in vitro with immunosuppressants. Transplantation 2006; 82: 1352-1361.
15. Barozzi P, Bonini C, Potenza L et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008; 86: 738-744.
16. Pearce EL, Walsh MC, Cejas PJ et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009; 460: 103-107.
17. Pescovitz MD, Nezakatgoo N, Lorber MI et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009; 88: 1010-1018.
18. Prlic M, Bevan MJ. Immunology: a metabolic switch to memory. Nature 2009; 460: 41-42.
19. Thaunat O, Beaumont C, Chatenoud L et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 2005; 80: 1212-1219.
20. Saemann MD, Haidinger M, Hecking M et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant 2009; 9: 2655-2661.
21. Saemann MD, Remuzzi G. Transplantation: time to rethink immunosuppression by mTOR inhibitors? Nat Rev Nephrol 2009; 5: 611-612.
22. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
23. Ruggenenti P, Perico N, Gotti E et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007; 84: 956-964.
24. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
25. Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 2001; 71: 1091-1097.
26. Servais A, Meas-Yedid V, Toupance O et al. Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. Am J Transplant 2009; 9: 2552-2560.
27. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990; 1: 76-83.
28. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522-2531.
29. Vollenbroker B, George B, Wolfgart M et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 2009; 296: F418-F426.
30. Torras J, Herrero-Fresneda I, Gulias O et al. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 2009; 24: 3632-3640.
31. Coombes JD, Mreich E, Liddle C et al. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005; 68: 2599-2607.
32. Letavernier E, Pe'raldi MN, Pariente A et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198-1203.
33. Letavernier E, Bruneval P, Mandet C et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2: 326-333.
34. Lieberthal W, Fuhro R, Andry CC et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-F706.
35. McTaggart RA, Gottlieb D, Brooks J et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-423.
36. Bonegio RG, Fuhro R, Wang Z et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16: 2063-2072.
37. Austin HABMJ, Howard LV, Kopp JB et al. Sirolimus therapy in idiopathic and lupus membranous nephropathy [abstract]. J Am Soc Nephrol 2008; 19: 561A.
38. Hoogeveen RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 1244-1250.
39. Kasiske BL, de Mattos A, Flechner SM et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392.
40. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551-559.
41. Johnston O, Rose CL, Webster AC et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
42. Di Paolo S, Teutonico A, Leogrande D et al. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006; 17: 2236-2244.
43. Lewis GF, Carpentier A, Adeli K et al. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-229.
44. Syed NA, Khandelwal RL. Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 2000; 211: 123-136.
45. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117: 2553-2561.
46. Kahan BD. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Transplant Proc 2008; 40: S17-S20.
47. Maiorano A, Stallone G, Schena A et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 2006; 82: 908-912.
48. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264-268.
49. Stallone G, Infante B, Grandaliano G et al. Management of side effects of sirolimus therapy. Transplantation 2009; 87: S23-S26.
50. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007; 7: 714-717.
51. Flechner SM, Zhou L, Derweesh I et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76: 1729-1734.
52. Tiong HY, Flechner SM, Zhou L et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87: 296-302.
53. Zuber J, Anglicheau D, Elie C et al. Sirolimus may reduce fertility in male renal transplant recipients. Am J Transplant 2008; 8: 1471-1479.
54. Alfadhli E, Koh A, Albaker W et al. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transpl Int 2009; 22: 622-625.
55. Cure P, Pileggi A, Froud T et al. Alterations of the female reproductive system in recipients of islet grafts. Transplantation 2004; 78: 1576-1581.
56. Garrean S, Massad MG, Tshibaka M et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005; 19: 698-703.
57. Morelon E, Stern M, Israel-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787-790.
58. Vlahakis NE, Rickman OB, Morgenthaler T. Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 2004; 79: 541-545.
59. Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet 2009; 373: 1235-1236.
60. Yu K, Shi C, Toral-Barza L et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010; 70: 621-631.
61. Yuan R, Kay A, Berg WJ et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009; 2: 45.
62. Nam JH. Rapamycin: could it enhance vaccine efficacy? Expert Rev Vaccines 2009; 8: 1535-1539.
63. Benavides CA, Pollard VB, Mauiyyedi S et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007; 84: 83-88.
64. Egli A, Kohli S, Dickenmann M et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation 2009; 88: 1161-1168.
65. Heredia A, Latinovic O, Gallo RC et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci USA 2008; 105: 20476-20481.
66. Durrbach A, Rostaing L, Tricot L et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of kidney from an expanded criteria donor. Transplantation 2008; 85: 486-490.
67. Pescovitz MD, Vincenti F, Hart M et al. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007; 64: 758-771.
68. Flechner SM, Goldfrab D, Solez K et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892.
69. Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.